BEXMAB
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 181 patients (estimated)
- Sponsors
- Faron Pharmaceuticals Ltd
- Tags
- BCL-2 Inhibitor, Monoclonal Antibody, Clever-1
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1753
- NCT Identifier
- NCT05428969
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.